Orthocell Ltd: Strong Sales Drives Acceleration of Remplir Global Expansion
Orthocell Ltd: Orthocell Receives $3.18 million R&D Tax Refund
Orthocell Ltd: Quarterly Activity Report & Appendix 4C
Orthocell Ltd: Notification regarding unquoted securities - OCC
Orthocell Ltd: Application for quotation of securities - OCC
Orthocell Ltd: Application for quotation of securities - OCC
Orthocell Ltd: Option Terms and Conditions
Orthocell Ltd: Proposed issue of securities - OCC
Orthocell Ltd: Third Consecutive Quarter of Record Revenue for Orthocell
Orthocell Ltd: US FDA Application Submitted for Remplir as US Launch Nears
Orthocell Ltd: Major Milestone with First Sales of Remplir in Singapore
Orthocell Ltd: Application for quotation of securities - OCC
Orthocell Ltd: Cleansing Notice
Orthocell Ltd: Change of Director's Interest Notice-John Van Der Wielen
Orthocell Ltd: Application for quotation of securities - OCC
Orthocell Ltd: Notification regarding unquoted securities - OCC
Orthocell Ltd: Change of Director's Interest Notice-Paul Anderson
Orthocell Ltd: Notification regarding unquoted securities - OCC
Orthocell Ltd: Outstanding Remplir Study Results Pave Way for FDA Clearance
Orthocell Ltd: Results of Annual General Meeting